NCT02623491View on ClinicalTrials.gov

Study to Investigate the Safety, Tolerability, and Pharmacokinetics of JNJ-55375515 in Healthy Participants

PHASE1CompletedINTERVENTIONAL

Enrollment

175

Participants

Timeline

Start Date

November 30, 2015

Primary Completion Date

September 30, 2016

Study Completion Date

September 30, 2016

Conditions

Healthy

Interventions

DRUG

JNJ-55375515

Participants will receive JNJ-55375515 at a starting dose of 0.75 milligrams (mg) and maximum escalated dose will be 200 mg.

DRUG

Placebo

Participants will receive matching placebo.

Trial Locations (1)

Unknown

Merksem

All Listed Sponsors

lead

Janssen Research & Development, LLC

INDUSTRY

NCT02623491 - Study to Investigate the Safety, Tolerability, and Pharmacokinetics of JNJ-55375515 in Healthy Participants | Biotech Hunter | Biotech Hunter